Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2.99 | 2.99 | 0.00 |
Stocks | 97.01 | 97.01 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 21.73 | 23.69 |
Price to Book | 4.88 | 4.66 |
Price to Sales | 3.69 | 3.48 |
Price to Cash Flow | 14.29 | 16.67 |
Dividend Yield | 1.20 | 1.25 |
5 Years Earnings Growth | 14.02 | 13.32 |
Name | Net % | Category Average |
---|---|---|
Financial Services | 25.24 | 13.80 |
Healthcare | 19.03 | 15.78 |
Technology | 16.02 | 27.89 |
Communication Services | 13.23 | 8.51 |
Consumer Defensive | 12.96 | 7.09 |
Industrials | 7.21 | 11.97 |
Consumer Cyclical | 6.32 | 12.12 |
Number of long holdings: 34
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Visa A | US92826C8394 | 6.59 | 309.92 | +0.01% | |
Alphabet A | US02079K3059 | 6.49 | 164.76 | -1.71% | |
Mastercard | US57636Q1040 | 5.58 | 520.86 | +1.12% | |
Microsoft | US5949181045 | 5.46 | 417.00 | +1.00% | |
Heineken | NL0000008977 | 4.90 | 60.65 | +0.92% | |
Fiserv | US3377381088 | 4.84 | 221.56 | +1.91% | |
Roche Holding Participation | CH0012032048 | 4.70 | 254.30 | +1.27% | |
Meta Platforms | US30303M1027 | 4.53 | 559.14 | -0.70% | |
Experian | GB00B19NLV48 | 4.45 | 3,809.0 | +2.67% | |
Agilent Technologies | US00846U1016 | 3.73 | 133.84 | +1.35% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Troy Trojan S Acc | 71.94M | 0.13 | 4.48 | 5.45 | ||
Troy Trojan S Inc | 137.52M | 0.12 | 4.47 | 5.46 | ||
Troy Trojan O Acc | 921.91M | 0.08 | 4.21 | 5.18 | ||
Troy Trojan O Inc | 205.24M | 0.08 | 4.21 | 5.18 | ||
GB00BZ6CNS31 | 2.01B | 6.00 | 2.44 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review